CNS Pharmaceuticals, Inc.
CNSP
$1.12
-$0.005-0.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.66% | -13.71% | -19.40% | -25.39% | -20.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.01% | -8.26% | -8.68% | 2.58% | 23.57% |
| Operating Income | 21.01% | 8.26% | 8.68% | -2.58% | -23.57% |
| Income Before Tax | 21.18% | 8.36% | 8.77% | -2.40% | -23.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.18% | 8.36% | 8.77% | -2.40% | -23.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.18% | 8.36% | 8.77% | -2.40% | -23.42% |
| EBIT | 21.01% | 8.26% | 8.68% | -2.58% | -23.57% |
| EBITDA | 21.01% | 8.26% | 8.66% | -2.61% | -23.64% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |